14.74 0.00 (0.00%)
After hours: 4:42PM EST
|Bid||10.00 x 800|
|Ask||15.94 x 900|
|Day's Range||13.68 - 14.78|
|52 Week Range||6.75 - 39.50|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.50|
- Within 90 Days of FDA PDUFA Action Date for DWP-450 - - Granted Marketing Approval for DWP-450 by Health Canada - - Conference Call Today at 4:30PM ET - IRVINE, Calif.,.
IRVINE, Calif., Nov. 01, 2018 -- Evolus, Inc. (NASDAQ:EOLS), a company dedicated to aesthetic medicine, announced today that members of management will be participating in two.
Evolus, Inc. (EOLS), a company dedicated to aesthetic medicine, today announced the expansion of its leadership team with the appointments of three key executives reporting to David Moatazedi, President and Chief Executive Officer. Evolus has appointed Kurt Knab as Vice President of Sales, Alejandro “Alex” Sabad as Vice President of Operations and Amy Marinne Fox as Vice President of Human Resources.
NEW YORK, Oct. 22, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
If you want to know who really controls Evolus Inc (NASDAQ:EOLS), then you’ll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, Read More...
IRVINE, Calif., Oct. 18, 2018 -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced that it will release 2018 third quarter financial.
IRVINE, Calif., Sept. 20, 2018-- Evolus, Inc., a company dedicated to aesthetic medicine, announced today that members of management will present at the Cantor Global Healthcare Conference in New York, ...
Evolus, Inc. (EOLS), a company dedicated to aesthetic medicine, today announced the appointment of Ashwin K. Agarwal as Vice President, Finance, Investor Relations, and Treasury, effective immediately. Mr. Agarwal joins Evolus from Alder BioPharmaceuticals where he served as Vice President, Corporate Strategy and brings with him over 20 years of both operational and corporate finance, investor relations, and accounting experience, from his time at both early and late stage healthcare companies. Earlier in his career, Mr. Agarwal served as Vice President, Finance and Investor Relations at a medical aesthetics start-up and also held roles of increasing responsibility at Allergan for fifteen years, most recently as Senior Director of Finance and Investor Relations.
Evolus, Inc. (EOLS), a company dedicated to aesthetic medicine, today announced the acceptance of its resubmission of its Biologics License Application for its lead product candidate, prabotulinumtoxinA (DWP-450), by the U.S. Food and Drug Administration (“FDA”). The FDA considered the resubmission a Class 2 response and has assigned a February 2, 2019 action date per the Prescription Drug User Fee Act (PDUFA).
The first new aesthetic neurotoxin to rival Allergan Plc’s Botox in almost a decade may be approved in time for Valentine’s Day. Evolus Inc. Chief Executive Officer David Moatazedi says his company remains on track for a spring 2019 launch for its experimental wrinkle treatment, DWP-450. The Food and Drug Administration is now expected to make a decision on the drug by February 2 after the company failed to secure approval in May when the agency had questions on the company’s chemistry, manufacturing and controls processes.
LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on EOLS sign up now at www.wallstequities.com/registration. On Tuesday, July 24, 2018, the Dow Jones Industrial Average and the S&P 500 edged 0.79% and 0.48% higher, respectively at the closing bell, while the NASDAQ Composite stayed bearish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Drugs - Generic equities this morning: Evolus Inc. (EOLS), Fibrocell Science Inc. (NASDAQ: FCSC), Flexion Therapeutics, Inc. (NASDAQ: FLXN), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA).
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 18) Abbott Laboratories (NYSE: ABT )(reported better-than-expected ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...
The market for initial public offerings (IPOs) of stock in the U.S. has been been hotter than a firecracker in 2018. In the first half of the year, 120 companies have gone public in the U.S., raising $35.2 billion in the process, according to data from Dealogic cited by The Wall Street Journal. IPOs brought to market so far in 2018 have produced an average gain of 22% for investors, per the Journal.